Gertrude Chimeka Anyanwoke, MD
Internal Medicine · Baton Rouge, LANPI 1760465421
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.2% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Viiv Healthcare Company at 28.1% of the total. Reporting peaked in 2019 at $1,190 and has fallen 94.5% since, to $65 in 2023.
Across 98 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$432
- Merck$306
- Johnson & Johnson$221
- Paratek Pharmaceuticals, Inc.$91
- Theratechnologies Inc.$71
- Napo Pharmaceuticals Inc$70
- plus $349 from 9 others
Across 37 payments — averaging $16,482 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$610K
What the payments were for
- Speaking & faculty fees$523%
- Food & beverage$1,42092%
- Education$684%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 27 | $432 |
| Merck | 22 | $306 |
| Johnson & Johnson | 20 | $221 |
| Paratek Pharmaceuticals, Inc. | 5 | $91 |
| Theratechnologies Inc. | 4 | $71 |
| Napo Pharmaceuticals Inc | 2 | $70 |
| Insmed, Inc. | 4 | $63 |
| Janssen Products, LP | 1 | $55 |
| Smith+Nephew | 3 | $55 |
| Novo Nordisk | 1 | $40 |
| Gilead | 2 | $39 |
| Mayne Pharma Commercial LLC | 2 | $30 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $29 |
| Astellas Pharma US Inc | 2 | $25 |
| AbbVie | 1 | $13 |
How this compares
$1,540 in reported general payments places this provider in the 70th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 46 | $192,606 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 44 | $177,323 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 25 | $123,849 |
| DovatoDolutegravir Sodium/Lamivudine | 35 | $108,687 |
| CabenuvaCabotegravir/Rilpivirine | 14 | $90,878 |
| PerserisRisperidone | 19 | $56,805 |
| Invega SustennaPaliperidone Palmitate | 13 | $47,364 |
| CompleraEmtricita/Rilpivirine/Tenof Df | 12 | $44,349 |
| OzempicSemaglutide | 38 | $36,676 |
| TivicayDolutegravir Sodium | 12 | $28,642 |
| MounjaroTirzepatide | 22 | $20,400 |
| EliquisApixaban | 28 | $18,680 |
| JardianceEmpagliflozin | 23 | $13,667 |
| Spiriva HandihalerTiotropium Bromide | 11 | $7,417 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,821 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTriumeq, Dovato, Cabenuva, Tivicay | $432 | $405,531105 claims |
| GileadBiktarvy | $39 | $192,60646 claims |
| Janssen Products, LPSymtuza | $55 | $123,84925 claims |
| Johnson & JohnsonInvega Sustenna, Complera | $221 | $91,71325 claims |
| Novo NordiskOzempic | $40 | $36,67638 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Baton Rouge
- Donna RyanBaton Rouge$991K
- John SchwabBaton Rouge$122K
- Barret MurphyBaton Rouge$43K
- Brian GremillionBaton Rouge$27K
- Bradley MeekBaton Rouge$20K
- Leo BlaizeBaton Rouge$17K
- Michael HymbaughBaton Rouge$16K
- Kyle ChampagneBaton Rouge$16K
- Charles HalliburtonBaton Rouge$16K
- Hartman BruntBaton Rouge$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.